DrugPatentWatch Information on Approved Drugs and Drug Products

Building Biotechnology: Starting, managing, and understanding
biotechnology companies

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents
To purchase a subscription and access the complete database, visit www.DrugPatentWatch.com

Drug Patent Expirations in July 2008
* Drugs may be covered by multiple patents or regulatory protections

Tradename Applicant Generic Name Patent Number Patent Expiration
CARDIOLITE Bristol Myers Squibb technetium tc-99m sestamibi kit 4,988,827 Jul 29, 2008
DEPAKOTE Abbott divalproex sodium 4,988,731 Jul 29, 2008
DEPAKOTE Abbott divalproex sodium 5,212,326 Jul 29, 2008
DEPAKOTE CP Abbott divalproex sodium 4,988,731 Jul 29, 2008
DEPAKOTE CP Abbott divalproex sodium 5,212,326 Jul 29, 2008
DEPAKOTE ER Abbott divalproex sodium 4,988,731 Jul 29, 2008
DEPAKOTE ER Abbott divalproex sodium 5,212,326 Jul 29, 2008
GLUCOTROL XL Pfizer glipizide 5,545,413 Jul 2, 2008
HIVID Roche zalcitabine 5,028,595 Jul 2, 2008
RESTORIL Tyco Hlthcare temazepam 5,030,632 Jul 9, 2008
RESTORIL Tyco Hlthcare temazepam 5,326,758 Jul 9, 2008
UVADEX Therakos methoxsalen 5,036,102 Jul 30, 2008
VEXOL Alcon rimexolone 4,686,214 Jul 22, 2008

SUBSCRIPTIONS

If this newsletter has been forwarded to you and you would like to subscribe, go to http://www.DrugPatentWatch.com/newsletter

If you no longer wish to receive this newsletter, go to http://www.DrugPatentWatch.com/newsletter/unsubscribe.php

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek independent professional advice before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

All trademarks and applicant names are the property of their respective owners or licensors.